35969-62-1

Basic information

• Product Name: 7-phenyl-1,6-naphthyridin-5-one
• Synonyms: 7-phenyl-1,6-naphthyridin-5-one
• CAS NO: 35969-62-1
• Molecular Weight: 222.246
• Mol File: 35969-62-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 7-phenyl-1,6-naphthyridin-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-phenyl-1,6-naphthyridin-5-one(35969-62-1)
• EPA Substance Registry System: 7-phenyl-1,6-naphthyridin-5-one(35969-62-1)

Safety Data

• Hazardous Substances Data: 35969-62-1(Hazardous Substances Data)

Upstream product

• 3222-56-8 2-methylnicotinic acid 
• 100-47-0 benzonitrile 
• 20577-26-8 2-bromonicotinonitrile 
• 118159-94-7 2-phenylethynylpyridine-3-carbonitrile 
• 64-17-5 ethanol 
• 1260150-44-4 C₁₆H₁₄N₂O 
• 536-74-3 phenylacetylene 

Downstream Products

• 1613435-77-0 1-methyl-5-oxo-7-phenyl-1,6-naphthyridinium iodide 
• 1613435-75-8 7-phenyl-1,6-naphthyridin-5-one 1-oxide 

Relevant articles and documents

TANKYRASE INHIBITORS

The present invention relates to a compound of formula I wherein X is C(R6) or N, Y is C or N, and ring A, ring B, R1 and R2 have the meanings defined herein, provided that when ring B is carbocyclic, X is C(R6); or a pharmaceutically acceptable salt or solvate thereof. The compounds are tankyrase-1 and tankyrase-2 inhibitors and are useful in the treatment of a number of conditions, including cancer.

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS

The invention relates to new substituted naphthyridines of formula (1), as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among -O-R3 or -NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6 R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, -C1-6-alkylen-O-C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and Formula (I) is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, -C1-3-alkyl, -C1-3-haloalkyl, -O-C1-3-alkyl, -C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.

Discovery and SAR of novel [1,6]naphthyridines as potent inhibitors of Spleen Tyrosine Kinase (SYK)

The discovery of novel 5,7-disubstituted[1,6]naphthyridines as potent inhibitors of Spleen Tyrosine Kinase (SYK) is discussed. The SAR reveals the necessity for a 7-aryl group with preference towards para substitution and that this in combination with 5-aminoalkylamino substituents further improved the potency of the compounds. The initial SAR as well as a survey of the other positions is discussed in detail.